MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,564,872
Unit: Dollar
Positive Cash Flow Breakdown
Prepaid expenses and other asset...
Unbilled receivable
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable
Repayment of financed insurance ...
Accrued expenses and other liabi...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-3,556,415
-2,767,969
-3,729,128
-3,679,090
Accrued interest
3,089
3,125
3,161
6,107
Change in fair value of liability classified warrants
-
35
998
9,063
Consultant compensation
-
414,951
50,717
203,014
Stock-based compensation
8,743
24,339
45,858
106,889
Amortization of orginal issue discount and debt issuance costs
-
-
-
0
Depreciation expense
6,533
6,533
-
-
Unbilled receivable
-420,345
415,934
-1,200,568
1,080,864
Prepaid expenses and other assets
-1,292,926
1,219,459
-779,709
-1,185
Accounts payable
-1,663,513
2,709,279
-579,374
-314,247
Accrued expenses and other liabilities
-12,633
-280,663
363,308
351,789
Net cash used in operating activities
-3,500,925
-1,525,833
-1,866,179
-4,414,280
Investment in property and equipment
-
0
123,643
-
Net cash flows used in investing activities
-
0
-123,643
-
Repayment of convertible notes
-
-
-
0
Proceeds from public offerings
-
0
0
1,100,007
Proceeds from warrant exercises
-
684,358
1,496,854
390,855
Proceeds from warrant inducement, net of issuance costs
-
0
0
2,200,012
Transaction costs from public offerings
-
-
0
204,193
Proceeds from issuance of series b preferred stock
-
3,975,000
-
-
Transaction costs associated with public offering and warrant inducements
-
204,193
5,410
291,611
Transaction costs associated with series b preferred stock issuance
-
391,376
-
-
Repayment of financed insurance premiums
63,947
105,013
39,979
71,292
Net cash (used in) provided by financing activities
-63,947
4,162,969
1,451,465
3,123,778
Decrease in cash and cash equivalents
-3,564,872
2,637,136
-538,357
-1,290,502
Cash and cash equivalents beginning of period
4,310,354
1,673,218
3,502,077
-
Cash and cash equivalents end of period
745,482
4,310,354
1,673,218
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Decrease in cash and cash
equivalents
-$3,564,872
Prepaid expenses and
other assets
-$1,292,926
Unbilled receivable
-$420,345
Stock-based compensation
$8,743
Depreciation expense
$6,533
Accrued interest
$3,089
Net cash used in
operating activities
-$3,500,925
Net cash (used in)
provided by financing...
-$63,947
Canceled cashflow
$1,731,636
Net loss
-$3,556,415
Repayment of financed
insurance premiums
$63,947
Accounts payable
-$1,663,513
Accrued expenses and
other liabilities
-$12,633
Buy us a coffee
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)